Emerging Clinical Initiatives in Pharmaceutical Development:
Methodology and Regulatory Perspectives
- The detailed information to join short courses, keynotes, parallel sessions, poster session and job fair will be emailed directly to those who registered to these events on April 19, 2021. Please contact Xiaofei Wang at firstname.lastname@example.org if you fail to receive the email by the end of April 19.
- Given evolving public concerns regarding COVID-19 and the potential travel uncertainties, the leadership team has decided to postpone the annual symposium to April 21-23, 2021 and this event will be hosted entirely on Zoom meetings/webinars. More details can be found in the Announcements tab.
The Duke-Industry Statistics Symposium (DISS) is organized by the Department of Biostatistics and Bioinformatics, Duke University School of Medicine and co-sponsored by Amgen, ASA-NC Chapter, Boehringer-Ingelheim, Genentech, ICSA, IQVIA, Janssen, Journal of Biopharmaceutical Statistics, Lilly, Merck, Otsuka, Parexel, PPD, SAS, UCB and ViiV. The symposium was established seven years ago to discuss challenging issues and recent advances related to the clinical development of drugs, biologics and devices and to promote research and collaboration among statisticians from industry, academia, and regulatory agencies.
|SAS||IQVIA||Eli Lilly and Company||Janssen|
|Otsuka||Journal of Biopharmaceutical Statistics||Intnat'l Chinese Statistical Association||ASA NC Chapter|